According to Vilas Chavan, Deputy Engineer (Water Supply) at PMC, water supply from MJP’s Patalganga River reduces on Sundays and Mondays. Additionally, frequent electric shutdowns and technical ...

Formosa and Cipla's agreement grants Cipla exclusive marketing rights for APP13007 in 11 countries, enhancing Cipla's ophthalmology portfolio. APP13007, approved by the FDA in March 2024, provides a ...

Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol propionate ophthalmic suspension 0.05% (APP13007) across 11 countries, including ...

On the downside, Rs 6,450 is an important support level to watch. Cipla is in a healthy short-term uptrend. After a recent correction, the stock has bounced from around Rs 1,400, where it also ...

This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits. "Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected ...

Cipla's stock is priced at Rs 1462.70, reflecting a percentage change of 3.03% for today. The current 7-day simple moving average (SMA7) is Rs 1449.52. Cipla's shares are currently priced at Rs ...

Cipla's current price stands at Rs 1429.0, reflecting a 1.95% rise today, while its three-month returns have dipped by 4.53%. Cipla has achieved a positive price breakout and is trading above its ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have started manufacturing key medicines for such diseases in the country.

Explore Cipla stock price history with detailed daily historical prices, including open, high, low, and volume data. Review stock chart history to analyze past trends and find the highest Cipla price.

Drug major Cipla expects to commence supplies to the US market from its China facility in ... Sharing updates about other plants, he noted that the facilities of Patalganga and Kurkumbh in India were ...

Torrent Pharmaceuticals has emerged as a frontrunner to acquire its rival Cipla with a non-binding offer that’s more than 30 per cent higher than American private equity giant Blackstone’s bid.

Engulfing Bearish 1H 69 Mar 19, 2025 08:30 ...